
Opinion|Videos|March 24, 2025
Aligning Treatment Goals: Key Considerations for Patients and Caregivers in Late-Line RRMM
Author(s)Saad Usmani, MD, Amrita Krishnan, MD
Panelists discuss how quality of life priorities shift in late-line multiple myeloma treatment, with patients emphasizing the importance of maintaining independence in daily activities, preserving cognitive function, managing pain effectively, minimizing treatment-related side effects that impact social engagement, balancing treatment schedules to allow for meaningful family time and personal milestones and finding psychological peace through spirituality or support systems—ultimately revealing that while disease control remains critical, the ability to live with purpose and dignity increasingly shapes treatment decisions as patients progress through multiple therapy lines.
Advertisement
Video content above is prompted by the following:
- What quality of life factors are most important to you at this stage of your treatment journey?
Advertisement
Related to this article

Among U.S. adults with a history of cancer, 45.8% reported drinking alcohol in the past 30 days in both 2016 and 2024, while drinking declined among adults without cancer, according to a study in Cancer Causes & Control of nearly 4 million adults.

Dr. Matteo Lambertini explains how Lynkuet reduced hot flashes in people on endocrine therapy for breast cancer, no matter when their treatment began.

Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, discusses why every patient with glioblastoma should have their tumor profiled, and what patients can ask their care team.

A breast surgeon explains why patients should raise lymphedema with their care team at the start of treatment, and how early detection can make it reversible.

A woman treated for DCIS breast cancer with a double mastectomy shares why her smoother recovery left her with survivor guilt and feeling like an impostor.

The FDA granted accelerated approval to Rybrevant Faspro for recurrent or metastatic head and neck cancer that grew after chemotherapy and immunotherapy.

Dr. Sara Hurvitz explains why giving Enhertu before surgery didn't change care for HER2-low, HR-positive early breast cancer, and what patients should know.
Advertisement
Advertisement
Trending on CURE
1
What Is a Whipple Procedure? Pancreatic Cancer Surgery Explained
2
Pancreatic Cancer and Enzyme Pills: Why They Matter at Every Meal
3
Enhertu Before Surgery Falls Short in HER2-Low Early Breast Cancer
4
Glioblastoma Genomic Testing: What Patients Should Ask
5

